JNJ's Profit Collapses 96% on Likely Talc Charge, Yet Guidance Rises

What happened

Johnson & Johnson reported a 96% year-over-year collapse in quarterly profit, a decline that appears driven by a massive one-time charge rather than operational deterioration. Despite the headline plunge, management raised its full-year adjusted guidance on the same day, signaling confidence in underlying business momentum. The company also extended its dividend streak to 64 consecutive years, underscoring its commitment to shareholder returns even amid significant legal and transition pressures. However, the size of the earnings hit raises immediate concerns that the talc liability reserve was materially increased, a risk that prior analysis flagged as unbounded. The divergence between GAAP earnings and raised guidance forces investors to scrutinize the exact nature of the charge before viewing the report as either positive or negative.

Implication

The profit collapse is almost certainly a symptom of a material talc accrual increase, directly challenging the thesis that litigation exposure remains contained. Yet the raised full-year guidance suggests that operational growth is tracking ahead of earlier fears, potentially indicating that STELARA erosion and CVS formulary impacts are less severe than modeled. The dividend increase is a positive signal of cash flow durability but does little to offset the open-ended talc risk, which management still cannot quantify. Until the company discloses the exact composition of the charge, the stock's current valuation remains too high relative to the asymmetric downside from litigation. Maintain a WAIT stance, but lower the attractive entry point below $200 to reflect increased uncertainty about eventual talc costs.

Thesis delta

The master thesis expected a WAIT pending Q2-Q3 evidence on talc and STELARA. This earnings release provides that evidence: a massive profit decline likely from a talc reserve increase, while adjusted guidance was raised. The net effect is that talc risk remains unbounded, so we retain WAIT but revise the attractive entry down to $190 to reflect heightened uncertainty.